Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
mNSCLC - L1 - PDL1 positive, durvalumab plus tremelimumab vs. all, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results MYSTIC (DT ; PDL1>25%), 2020 0.85 [0.61; 1.18]
0.85 [0.61 ; 1.18 ] MYSTIC (DT ; PDL1>25%), 2020 1 0% 325 NA not evaluable progression or deaths (PFS)detailed results MYSTIC (DT ; PDL1>25%), 2020 1.05 [0.72; 1.53]
1.05 [0.72 ; 1.53 ] MYSTIC (DT ; PDL1>25%), 2020 1 0% 325 NA not evaluable objective responses (ORR)detailed results MYSTIC (DT ; PDL1>25%), 2020 0.87 [0.55; 1.37]
0.87 [0.55 ; 1.37 ] MYSTIC (DT ; PDL1>25%), 2020 1 0% 325 NA not evaluable AE (any grade)detailed results MYSTIC (DT ; PDL1>25%), 2020 0.43 [0.15; 1.24]
0.43 [0.15 ; 1.24 ] MYSTIC (DT ; PDL1>25%), 2020 1 0% 316 NA not evaluable AE (grade 3-4)detailed results MYSTIC (DT ; PDL1>25%), 2020 0.86 [0.56; 1.35]
0.86 [0.56 ; 1.35 ] MYSTIC (DT ; PDL1>25%), 2020 1 0% 316 NA not evaluable AE leading to death (grade 5)detailed results MYSTIC (DT ; PDL1>25%), 2020 3.45 [1.24; 9.59]
3.45 [1.24 ; 9.59 ] MYSTIC (DT ; PDL1>25%), 2020 1 0% 316 NA not evaluable AE leading to treatment discontinuation (any grade)detailed results MYSTIC (DT ; PDL1>25%), 2020 1.63 [0.91; 2.93]
1.63 [0.91 ; 2.93 ] MYSTIC (DT ; PDL1>25%), 2020 1 0% 316 NA not evaluable SAE (any grade)detailed results MYSTIC (DT ; PDL1>25%), 2020 1.93 [1.22; 3.04]
1.93 [1.22 ; 3.04 ] MYSTIC (DT ; PDL1>25%), 2020 1 0% 316 NA not evaluable STRAE (any grade)detailed results MYSTIC (DT ; PDL1>25%), 2020 1.05 [0.59; 1.87]
1.05 [0.59 ; 1.87 ] MYSTIC (DT ; PDL1>25%), 2020 1 0% 316 NA not evaluable TRAE (any grade)detailed results MYSTIC (DT ; PDL1>25%), 2020 0.17 [0.09; 0.30]
0.17 [0.09 ; 0.30 ] MYSTIC (DT ; PDL1>25%), 2020 1 0% 316 NA not evaluable TRAE (grade 3-4)detailed results MYSTIC (DT ; PDL1>25%), 2020 0.36 [0.22; 0.60]
0.36 [0.22 ; 0.60 ] MYSTIC (DT ; PDL1>25%), 2020 1 0% 316 NA not evaluable TRAE leading to death (grade 5)detailed results MYSTIC (DT ; PDL1>25%), 2020 0.94 [0.06; 15.13]
0.94 [0.06 ; 15.13 ] MYSTIC (DT ; PDL1>25%), 2020 1 0% 316 NA not evaluable TRAE leading to discontinuation (any grade)detailed results MYSTIC (DT ; PDL1>25%), 2020 1.04 [0.54; 2.03]
1.04 [0.54 ; 2.03 ] MYSTIC (DT ; PDL1>25%), 2020 1 0% 316 NA not evaluable 0.0 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-11-01 00:43 +01:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 171
- treatments: 634,861